| Editor’s Note: Getting ready for #ASH22? Fierce Pharma will talk to Dr. Naveen Pemmaraju at MD Anderson in a Twitter chat about the latest advances in blood cancer. Search #FierceTalksASH starting at 4pm ET on Dec. 8 to join the conversation. Our team will also be on site in New Orleans to bring you fresh data from the annual conference. |
|
For researchers unaffiliated with an academic library, finding scientific papers can be time-consuming and expensive—and organizing or sharing them can be even harder. Can a new tool address this gap? Learn more. 
|
|
Today's Big NewsDec 6, 2022 |
| By Angus Liu In a potential key battleground for KRAS inhibitors that involves combination with Merck's PD-1 king Keytruda, Mirati's adagrasib appears to be pulling ahead of Amgen’s first-to-market Lumakras in the latest clinical data revelation. But Mirati's stock price still tanked. |
|
|
|
By Nick Paul Taylor The dominoes keep falling in the PI3K space. After meeting with the FDA, Kyowa Kirin and MEI Pharma have stopped development of their B-cell malignancy prospect zandelisib outside of Japan. |
By Nick Paul Taylor Pfizer’s COVID-19 drug Paxlovid has rapidly grown into a $22 billion-a-year mega blockbuster. Now, the Big Pharma wants to develop a sibling to the antiviral—and has identified Clear Creek Bio as an ally that can help make it happen. |
By Gabrielle Masson AbbVie has formed a connection with HotSpot, inking a global licensing option deal for the biotech’s preclinical small-molecule allosteric therapy and extending the opportunity to make up to $295 million in biobucks. |
|
Hear DDI expert, Dr. Brian Ogilvie, discuss the important takeaways from the draft global guideline in this new webinar... Read More & Register >> 
|
|
By Max Bayer Gossamer bio is celebrating a phase 2 win after a series of fails, but analysts aren't popping the champagne just yet. |
By Max Bayer Editas is looking to bounce back after shelving its top asset, touting an extremely small sample size of sickle cell patients treated with its gene editing therapy. |
By Helen Floersh Researchers have developed an assay that detects the toxic oligomers that drive Alzheimer’s disease progression. The peptide that makes the test work could one day be used as a treatment. |
By Annalee Armstrong Women, Asian and Black participants were underrepresented in more than 100 clinical trials for COVID-19 drugs and vaccines, a new analysis has found. Meanwhile, Hispanic and Latino participants were overrepresented, according to the study published in JAMA Internal Medicine Monday. |
By Andrea Park Months after Neuralink shot down allegations of “horrific abuse” in its animal testing practices, the U.S. Department of Agriculture’s inspector general has reportedly opened an investigation into the accusations against Elon Musk’s brain-computer interface company. |
By Joseph Keenan Worldwide Clinical Trials named Pete Duprat to head its growing early-phase business unit, which includes the CRO’s recently expanded Bioanalytical Center of Excellence in Austin, Texas. |
By Fraiser Kansteiner In the latest legal entanglement, Teva is accused of stalling the rollout of its generic EpiPen in a quid pro quo with the epinephrine injector’s owner, Viatris. In return for the epinephrine launch delay, Viatris promised not to undercut Teva’s branded narcolepsy med Nuvigil with its own generic, according to court documents filed earlier this month. |
By Frank Diamond Eleven percent of people who’ve been hospitalized with COVID-19 have damaged lungs, according to a new study. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the current state of Biogen and recent investor reactions to the new hire. Plus we cover the week's news including: What Albert Bourla said that has him in hot water, a $3.5 million drug, and we tease a possible major acquisition. |
|
|---|
|
|
|
Thursday, December 15, 2022 | 11am ET / 8am PT Cell therapy products have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. In this webinar we discuss what these key challenges are, how to approach these challenges and some opportunities available to better the process. Register now. 
|
|
Video Revolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
